It is known that close to 50% of patients with major depressive episodes may not achieve remission after the trials of first-line antidepressants, and only around one-third will achieve remission. This is clinically relevant for both patients and medical professionals, as chances of remission reduce with each subsequent trial.
Psychiatry Education Forum Academy is excited to release the first chapter of our lecture series on 10 Augmentation Strategies for MDD.
The first lecture in this series is on Atypical Antipsychotics. Atypical antipsychotics are recommended by most guidelines as an augmentation treatment for major depressive disorders.
Responses